New kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccine

Дата публикации: 06-08-2026 18:18:58

The flu shot, named mFlusiva, is intended for adults age 50 or older.
The post New kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccine appeared first on Boston.com.

Основное содержимое страницы с новостью.

WASHINGTON (AP) — The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, manufacturer Moderna said.

The shot, named mFlusiva, is intended for adults age 50 or older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.

While there already are multiple flu vaccine options in the U.S., including three specifically recommended for people age 65 or older, tens of thousands of Americans die from influenza every year and older adults are among the most vulnerable.

Flu vaccines must be updated annually to best match circulating strains of the virus. Vaccines made with the Nobel Prize-winning mRNA technology are faster to manufacturer than other types, and experts say this additional option might help if the shape-shifting flu virus mutates in a way that requires suddenly brewing new doses.

Moderna said the FDA granted full approval for mFlusiva’s use in people ages 50 to 64, based on a study of 40,000 people that found 27% fewer flu cases among people who got the new shot compared with those who got a different common flu vaccine brand. For people 65 or older, the Cambridge, Massachusetts-based manufacturer said the FDA granted what’s called accelerated approval for the shot — based on a smaller study showing it generated a strong immune response compared with an existing high-dose vaccine for seniors – while it conducts an additional study.

Moderna’s data showed no major safety issues although the shot did cause some temporary reactions including injection site pain, fever, headache, tiredness and aches that occurred somewhat more than with today’s flu shots.

The FDA action comes after a highly unusual public dispute over mFlusiva earlier this year. A then-top FDA official blocked the company’s application, a sign of the agency’s heightened vaccine scrutiny under Health Secretary Robert F. Kennedy Jr. Days later, the agency changed course after Moderna publicly challenged the ruling — and in June a panel of independent advisers to the FDA unanimously recommended the vaccine’s approval.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA approves first mRNA-based flu vaccine	0	9.2	06-08-2026
2	FDA panel backs first-of-its-kind flu vaccine using mRNA technology	0	7	18-06-2026
3	FDA approves first mRNA flu vaccine	0	5.78	06-08-2026
4	FDA approves first mRNA flu vaccine	0	5.78	06-08-2026
5	First-of-its-kind flu shot may be approved for older adults	-2	6	18-06-2026
6	В Подмосковье началась вакцинация от гриппа взрослого населения	0	0	28-08-2025
7	Quick takes: Avian flu vaccine trial, antifungal drug discovery, untreated syphilis in Alabama	0	5	22-04-2026
8	Эксперты регулятора США рекомендовали бустерные дозы вакцины Moderna лицам старше 65 лет	0	0	14-10-2021
9	Гериатр Минздрава назвала две прививки, которые могут продлить жизнь	5	7	21-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 7.46. Источник: www.boston.com.